{"entity":{"id":"cadence-mirxes","kind":"trial","name":"Project CADENCE (Mirxes multi-cancer blood test)","aka":["CADENCE"],"tldr":"A Singapore study of up to 15,000 people developing Mirxes' blood test for nine cancers using microRNA, DNA methylation and proteins.","summary":"Project CADENCE (NCT05633342) is an observational study sponsored by MiRXES Pte Ltd. It develops and validates blood-based multi-cancer screening tests through a multi-omic approach combining microRNA, DNA methylation, RNA and protein markers.\n\nThe registry record, read on 29 October 2026, gives its status as unknown (the sponsor last updated it on 20 March 2023), with an estimated 15,000 participants, a start on 7 July 2022 and primary completion expected in December 2024.","asOf":"2026-10-29","links":[{"label":"ClinicalTrials.gov NCT05633342","url":"https://clinicaltrials.gov/study/NCT05633342"}],"tags":[],"related":[],"cancers":[],"sections":["early-detection"],"technologies":["mced","liquid-biopsy"],"targets":[],"drugs":[],"companies":["mirxes"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05633342","phase":"observational","setting":"People with one of nine cancers and people without cancer in Singapore, developing a multi-omic blood test","sponsor":"MiRXES Pte Ltd","started":"2022-07-07","startedType":"actual","enrolled":15000,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/cadence-mirxes/","neighbours":{"section":[{"id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"}],"company":[{"id":"mirxes","kind":"company","name":"Mirxes","route":"/companies/mirxes/"}]}}